-
Device-Measured 24-Hour Movement Behaviors and Blood Pressure: A 6-Part Compositional Individual Participant Data Analysis in the ProPASS Consortium. Circulation (IF 35.5) Pub Date : 2024-11-06 Joanna M Blodgett,Matthew N Ahmadi,Andrew J Atkin,Richard M Pulsford,Vegar Rangul,Sebastien Chastin,Hsiu-Wen Chan,Kristin Suorsa,Esmée A Bakker,Nidhi Gupta,Pasan Hettiarachchi,Peter J Johansson,Lauren B Sherar,Borja Del Pozo Cruz,Nicholas Koemel,Gita D Mishra,Thijs M H Eijsvogels,Sari Stenholm,Alun D Hughes,Armando Teixeira-Pinto,Ulf Ekelund,I-Min Lee,Andreas Holtermann,Annemarie Koster,Emmanuel Stamatakis
BACKGROUND Blood pressure (BP)-lowering effects of structured exercise are well-established. Effects of 24-hour movement behaviors captured in free-living settings have received less attention. This cross-sectional study investigated associations between a 24-hour behavior composition comprising 6 parts (sleeping, sedentary behavior, standing, slow walking, fast walking, and combined exercise-like
-
Transseptal Transcatheter Valve-in-Valve Mitral Valve Implantation: Ready for Prime Time. Circulation (IF 35.5) Pub Date : 2024-11-04 Marina Urena
-
Letter by Zhao et al Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth". Circulation (IF 35.5) Pub Date : 2024-11-04 Jing Zhao,Qing-Liu Li,Peng-Zhou Hang
-
Treating Reproductive-Aged Women With Glucagon-Like Peptide-1 Receptor Agonists: What Are the Clinical Considerations? Circulation (IF 35.5) Pub Date : 2024-11-04 Garima Sharma
-
A Day Like Every Other Day: 2024 Perioperative Guidelines and Their Clinical Impact. Circulation (IF 35.5) Pub Date : 2024-11-04 Henry B Han,James B Froehlich
-
Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation (IF 35.5) Pub Date : 2024-11-04 Suzanne V Arnold,Kensey L Gosch,Chantal Dolan,Jennifer T Fine,Ahmad Masri,Sara Saberi,Andrew Wang,Perry M Elliott,Sheila M Hegde,Jenny Lam,Amy J Sehnert,Sharon Cresci,Richard G Bach,John A Spertus
-
Response by Caller et al to Letter Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth". Circulation (IF 35.5) Pub Date : 2024-11-04 Tal Caller,Crislyn D'Souza-Schorey,Nili Naftali-Shani,Jonathan Leor
-
The Cardiac Intensive Care Unit at Age 60. Circulation (IF 35.5) Pub Date : 2024-11-04 Erin A Bohula,David A Morrow
-
Cardiovascular Care in Canada: Strengths, Challenges, and Opportunities For Improvement. Circulation (IF 35.5) Pub Date : 2024-11-04 Tauben Averbuch,Krista Stelkia,Harriette G C Van Spall
-
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation (IF 35.5) Pub Date : 2024-11-04 Harpreet S Bhatia,Simon Wandel,Peter Willeit,Anastasia Lesogor,Keith Bailey,Paul M Ridker,Paul Nestel,John Simes,Andrew Tonkin,Gregory G Schwartz,Helen Colhoun,Christoph Wanner,Sotirios Tsimikas
BACKGROUND Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined. METHODS A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials
-
Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial. Circulation (IF 35.5) Pub Date : 2024-11-04 Hayley T Dillon,Nicholas J Saner,Tegan Ilsley,David S Kliman,Stephen J Foulkes,Christian J Brakenridge,Andrew Spencer,Sharon Avery,Piet Claus,David W Dunstan,Robin M Daly,Steve F Fraser,Neville Owen,Brigid M Lynch,Bronwyn A Kingwell,Andre La Gerche,Erin J Howden
BACKGROUND Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We conducted a randomized controlled trial testing whether a multicomponent activity intervention could attenuate reductions in cardiorespiratory fitness and exercise cardiac
-
Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial. Circulation (IF 35.5) Pub Date : 2024-10-30 Felix Rudolph,Martin Geyer,Stephan Baldus,Valeria Maria De Luca,Torsten Doenst,Roman Pfister,Jan Gummert,Mirjam Kessler,Peter Boekstegers,Edith Lubos,Jörg Schröder,Holger Thiele,Thomas Walther,Malte Kelm,Jörg Hausleiter,Ingo Eitel,Ulrich Fischer-Rasokat,Alexander Bufe,Alexander Schmeisser,Hüseyin Ince,Philipp Lurz,Ralph Stephan von Bardeleben,Christian Hagl,Thilo Noack,Sebastian Reith,Harald Beucher
-
Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial. Circulation (IF 35.5) Pub Date : 2024-10-29 Wissam A Jaber,Carin F Gonsalves,Stefan Stortecky,Samuel Horr,Orestis Pappas,Ripal T Gandhi,Keith Pereira,Jay Giri,Sameer J Khandhar,Khawaja Afzal Ammar,David M Lasorda,Brian Stegman,Lucas Busch,David J Dexter Ii,Ezana M Azene,Nikhil Daga,Fakhir Elmasri,Chandra R Kunavarapu,Mark E Rea,Joseph S Rossi,Joseph Campbell,Jonathan Lindquist,Adam Raskin,Jason C Smith,Thomas M Tamlyn,Gabriel A Hernandez,Parth
BACKGROUND There is a lack of randomized controlled trial (RCT) data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism (PE). METHODS PEERLESS is a prospective, multicenter, RCT that enrolled 550 intermediate-risk PE patients with right ventricular dilatation and additional clinical risk factors randomized 1:1 to treatment with large-bore mechanical
-
Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials. Circulation (IF 35.5) Pub Date : 2024-10-28 Elisabetta Patorno
-
Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management. Circulation (IF 35.5) Pub Date : 2024-10-28 Sean van Diepen,Janine Pöss,Janek M Senaratne,Ann Gage,David A Morrow
The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular
-
A Rhythm Hidden in the Details. Circulation (IF 35.5) Pub Date : 2024-10-28 Shasha Yu,Jingyu Jiao,Ming Liu
-
Oral Anticoagulation in Device Patients With Atrial High-Rate Episodes: Shared Decision-Making After ARTESIA and NOAH-AFNET-6. Circulation (IF 35.5) Pub Date : 2024-10-28 Christine M Albert
-
Association Between Delay to First Shock and Successful First-Shock Ventricular Fibrillation Termination in Patients With Witnessed Out-of-Hospital Cardiac Arrest. Circulation (IF 35.5) Pub Date : 2024-10-27 Remy Stieglis,Bas J Verkaik,Hanno L Tan,Rudolph W Koster,Hans van Schuppen,Christian van der Werf
BACKGROUND In patients with out-of-hospital cardiac arrest who present with an initial shockable rhythm, a longer delay to the first shock decreases the probability of survival, often attributed to cerebral damage. The mechanisms of this decreased survival have not yet been elucidated. Estimating the probability of successful defibrillation and other factors in relation to the time to first shock may
-
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention. Circulation (IF 35.5) Pub Date : 2024-10-27 Felice Gragnano,David van Klaveren,Dik Heg,Lorenz Räber,Mitchell W Krucoff,Sergio Raposeiras-Roubän,Jurriën M Ten Berg,Sergio Leonardi,Takeshi Kimura,Noé Corpataux,Alessandro Spirito,James B Hermiller,Emad Abu-Assi,Dean Chan Pin Yin,Jaouad Azzahhafi,Claudio Montalto,Marco Galazzi,Sarah Bär,Raminta Kavaliauskaite,Fabrizio D'Ascenzo,Gaetano M De Ferrari,Hirotoshi Watanabe,Philippe Gabriel Steg,Deepak
BACKGROUND Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding
-
In Which Patients Will PCI Relieve Angina? Circulation (IF 35.5) Pub Date : 2024-10-27 William F Fearon
-
Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock - a Secondary Analysis of the DanGer Shock Trial. Circulation (IF 35.5) Pub Date : 2024-10-27 Elric Zweck,Christian Hassager,Rasmus P Beske,Lisette O Jensen,Hans Eiskjær,Norman Mangner,Amin Polzin,P Christian Schulze,Carsten Skurk,Peter Nordbeck,Peter Clemmensen,Vasileios Panoulas,Sebastian Zimmer,Andreas Schäfer,Malte Kelm,Thomas Engstrøm,Lene Holmvang,Anders Junker,Henrik Schmidt,Christian J Terkelsen,Axel Linke,Ralf Westenfeld,Jacob E Møller,
BACKGROUND In the Danish-German Cardiogenic Shock (DanGer Shock) trial, use of a microaxial flow pump (mAFP) in patients with ST-segment elevation myocardial infarction (STEMI)-related CS led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed. METHODS In this international
-
End-Organ Injury and Failure: The True DanGer in Cardiogenic Shock. Circulation (IF 35.5) Pub Date : 2024-10-27 Saraschandra Vallabhajosyula
-
Conduction Disturbances and Outcome After Surgical Aortic Valve Replacement in Patients With Bicuspid and Tricuspid Aortic Stenosis. Circulation (IF 35.5) Pub Date : 2024-10-23 Johan O Wedin,Viktor Näslund,Sergey Rodin,Oscar E Simonson,Frank A Flachskampf,Stefan K James,Elisabeth Ståhle,Karl-Henrik Grinnemo
BACKGROUND This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aortic stenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively). Additionally, the study included stratification of BAV patients according to subtype
-
Bleeding After Cardiovascular Surgery: A Continuing Problem. Circulation (IF 35.5) Pub Date : 2024-10-21 Frank W Sellke
-
Against Odds of Prolonged Warm Ischemia: Early Experience With DCD Heart Transplantation After 20-Minute No-Touch Period. Circulation (IF 35.5) Pub Date : 2024-10-21 Gino Gerosa,Giovanni Battista Luciani,Nicola Pradegan,Vincenzo Tarzia,Tea Lena,Paolo Zanatta,Demetrio Pittarello,Francesco Onorati,Antonella Galeone,Leonardo Gottin,Massimo Boffini,Marinella Zanierato,Matteo Marro,Sofia Martin Suarez,Luca Botta,Paola Lilla Della Monica,Mariano Feccia,Guido Maria Olivieri,Amedeo Terzi,Alessandra Oliveti,Giuseppe Feltrin,Massimo Cardillo,Claudio Francesco Russo,Davide
-
Arterial-Lymphatic-Like Endothelial Cells Appear in Hereditary Hemorrhagic Telangiectasia 2 and Contribute to Vascular Leakage and Arteriovenous Malformations. Circulation (IF 35.5) Pub Date : 2024-10-21 Yang Yang,Xiuju Wu,Yan Zhao,Daoqin Zhang,Li Zhang,Xinjiang Cai,Jaden Ji,Zheng Jing,Kristina I Boström,Yucheng Yao
BACKGROUND Arteriovenous malformations (AVMs) are characteristic of hereditary hemorrhagic telangiectasia. Loss-of-function mutations in the activin receptor-like kinase 1 (Alk1) are linked to hemorrhagic telangiectasia type 2. METHODS Endothelial-specific deletion of Alk1, endothelial lineage tracing, transcriptomics of single-cell analysis, and electron microscopy were performed to examine the vascular
-
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation (IF 35.5) Pub Date : 2024-10-21 Li Shen,Pooja Dewan,João Pedro Ferreira,Jonathan W Cunningham,Pardeep S Jhund,Inder S Anand,Alvin Chandra,Lu-May Chiang,Brian Claggett,Akshay S Desai,Jianjian Gong,Carolyn S P Lam,Martin P Lefkowitz,Aldo P Maggioni,Felipe Martinez,Milton Packer,Margaret M Redfield,Jean L Rouleau,Dirk J van Veldhuisen,Faiez Zannad,Michael R Zile,Scott D Solomon,John J V McMurray
BACKGROUND Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood. METHODS We analyzed cognitive function, using the Mini-Mental State Examination (MMSE), in patients with heart failure and preserved ejection fraction enrolled in a prespecified substudy of the PARAGON-HF trial (Prospective
-
Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease. Circulation (IF 35.5) Pub Date : 2024-10-21 Marcel Benkhoff,Maike Barcik,Philipp Mourikis,Jana Dahlmanns,Paulina Kahmann,Philipp Wollnitzke,Moritz Hering,Tim Huckenbeck,Julia Hoppe,Nina Semleit,Jennifer Deister-Jonas,Saif Zako,Jasmin Seel,Cristina Coman,Mareike Barth,Mareike Cramer,Carolin Helten,Laura Wildeis,Hao Hu,Gabrielle Al-Kassis,Daniel Metzen,Julia Hesse,Jessica Weber,Lisa Dannenberg,Payam Akhyari,Artur Lichtenberg,Christine Quast,Norbert
BACKGROUND Aortic valve disease (AVD) is associated with high mortality and morbidity. To date, there is no pharmacological therapy available to prevent AVD progression. Because valve calcification is the hallmark of AVD and S1P (sphingosine-1-phosphate) plays an important role in osteogenic signaling, we examined the role of S1P signaling in aortic stenosis disease. METHODS AVD progression and its
-
Extracellular RIPK3 Acts as a Danger-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury. Circulation (IF 35.5) Pub Date : 2024-10-16 Wenjia Zhang,Junxia Zhang,Zeyuan Wang,Ting Li,Liu Changyun,Xuya Kang,Xiaomeng Cui,Jingli Yang,Huilin Qu,Jiaxin Duanmu,Ying Peng,Kai Wang,Li Jin,Peng Xie,Wen Zheng,Haibao Shang,Yahan Liu,Zhuang Tian,Zhenyu Liu,Ye Jin,Yingjia Li,Nan Li,Xiaozhen Zhuo,Yue Wu,Xiaolu Shi,Runhao Ma,Yueshen Sun,Kai Zhang,Xiangming Fang,Xiaomin Hu,Erdan Dong,Shuyang Zhang,Yan Zhang
BACKGROUND Cardiac ischemia/reperfusion (I/R) injury has emerged as an important therapeutic target for ischemic heart disease. Currently, there is no effective therapy for reducing cardiac I/R injury. Damage-associated molecular patterns are endogenous molecules released after cellular damage to exaggerate tissue inflammation and injury. RIPK3 (receptor-interacting protein kinase 3), a well-established
-
Patients With Advanced Heart Failure and Atrial Fibrillation Deserve an Attempt at Catheter Ablation as First-Line Therapy. Circulation (IF 35.5) Pub Date : 2024-10-14 Christian Sohns,Philipp Sommer
-
Pathogenesis of Atherothrombotic Events: From Lumen to Lesion and Beyond. Circulation (IF 35.5) Pub Date : 2024-10-14 Peter Libby
-
Response by Hoedemakers et al to Letter Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis". Circulation (IF 35.5) Pub Date : 2024-10-14 Sarah Hoedemakers,Bernard Cosyns,Steven Droogmans,Frederik H Verbrugge,Lieven Herbots,Jan Verwerft
-
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation (IF 35.5) Pub Date : 2024-10-14 Jennifer Linge,Andreas L Birkenfeld,Ian J Neeland
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle quantity, composition, and function. This primer aims to address whether muscle-related changes associated with
-
Letter by Jha Regarding Article, "mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis". Circulation (IF 35.5) Pub Date : 2024-10-14 Ajay Kumar Jha
-
Sustained but Decoyed Activation of the JAK1-STAT Pathway by Aberrant Protein Aggregation Exacerbates Proteotoxicity. Circulation (IF 35.5) Pub Date : 2024-10-14 Mingqi Cai,Bo Pan,Peng Xiao,Mark Bouska,Megan T Lewno,Yu Xing,Erliang Zeng,Huiyun Liang,Faqian Li,Xiang Gao,Xuejun Wang
-
Optical Spectroscopic Detection and Typing of Cardiac Amyloidosis. Circulation (IF 35.5) Pub Date : 2024-10-14 Sudipta S Mukherjee,Joseph J Maleszewski,Daniel Luthringer,Matthew P Confer,Anirudh Mittal,Surendra Dasari,Ellen D McPhail,Suraj Kapa,Thenkurussi Kesavadas,Andre Kajdacsy-Balla,Evan Kransdorf,Jai Raman,Rohit Bhargava
-
Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association. Circulation (IF 35.5) Pub Date : 2024-10-14 Rakesh Gopinathannair,Brian Olshansky,Mina K Chung,Steve Gordon,Jose A Joglar,Gregory M Marcus,Philip L Mar,Andrea M Russo,Uma N Srivatsa,Elaine Y Wan,
Cardiac arrhythmias are commonly noted in patients during infections with and recovery from COVID-19. Arrhythmic manifestations span the spectrum of innocuous and benign to life-threatening and deadly. Various pathophysiological mechanisms have been proposed. Debate continues on the impact of incident and exacerbated arrhythmias on the acute and chronic (recovery) phase of the illness. COVID-19 and
-
Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality. Circulation (IF 35.5) Pub Date : 2024-10-11 Günther Silbernagel,Yan Q Chen,Hongxia Li,Deven Lemen,Yi Wen,Eugene Y Zhen,Martin Rief,Marcus E Kleber,Graciela Delgado,Mark A Sarzynski,Yue-Wei Qian,Boerge Schmidt,Raimund Erbel,Ulrike Trampisch,Angela P Moissl,Henrik Rudolf,Heribert Schunkert,Andreas Stang,Winfried März,Hans J Trampisch,Hubert Scharnagl,Robert J Konrad
BACKGROUND ANGPTL3/4/8 (angiopoietin-like proteins 3, 4, and 8) are important regulators of LPL (lipoprotein lipase). ANGPTL8 forms complexes with ANGPTL3 and ANGPTL4. ANGPTL4/8 complex formation converts ANGPTL4 from a furin substrate to a plasmin substrate, and both cleavages generate similar C-terminal domain-containing (CD)-ANGPTL4 fragments. Whereas several studies have investigated associations
-
YAP Overcomes Mechanical Barriers to Induce Mitotic Rounding and Adult Cardiomyocyte Division. Circulation (IF 35.5) Pub Date : 2024-10-11 Yuka Morikawa,Jong H Kim,Rich Gang Li,Lin Liu,Shijie Liu,Vaibhav Deshmukh,Matthew C Hill,James F Martin
BACKGROUND Many specialized cells in adult organs acquire a state of cell cycle arrest and quiescence through unknown mechanisms. Our limited understanding of mammalian cell cycle arrest is derived primarily from cell culture models. Adult mammalian cardiomyocytes, a classic example of cell cycle arrested cells, exit the cell cycle postnatally and remain in an arrested state for the life of the organism
-
Letter by Aldaas et al Regarding Article, "Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials". Circulation (IF 35.5) Pub Date : 2024-10-07 Omar M Aldaas,Amer M Aldaas,Jonathan C Hsu
-
Response by McIntyre et al to Letter Regarding Article, "Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials". Circulation (IF 35.5) Pub Date : 2024-10-07 William F McIntyre,Alexander P Benz,Jeff S Healey,Renato Lopes
-
-
Challenges and Opportunities in Aortic Dissection: The Journey to Personalized Medicine. Circulation (IF 35.5) Pub Date : 2024-10-07 Marion A Hofmann Bowman,Kim A Eagle
-
Mex3a Protects Against Atherosclerosis: Evidence From Mice and Humans. Circulation (IF 35.5) Pub Date : 2024-10-07 Donato Santovito,James M Henderson,Kiril Bidzhekov,Vasiliki Triantafyllidou,Yvonne Jansen,Zhifen Chen,Floriana M Farina,Anastasiia Diagel,Maria Aslani,Xavier Blanchet,Heribert Schunkert,Remco T A Megens,Yvonne Döring,Michael Sattler,Christian Weber
-
Ablation Strategies for Repeat Procedures in Atrial Fibrillation Recurrences Despite Durable Pulmonary Vein Isolation: The Prospective Randomized ASTRO AF Multicenter Trial. Circulation (IF 35.5) Pub Date : 2024-10-07 Boris Schmidt,Stefano Bordignon,Andreas Metzner,Philipp Sommer,Daniel Steven,Tilmann Dahme,Matthias Busch,Roland Richard Tilz,David Schaack,Andreas Rillig,Christian Sohns,Arian Sultan,Karolina Weinmann-Emhardt,Astrid Hummel,Julia Vogler,Thomas Fink,Jakob Lueker,Alexander Pott,Christian Heeger,K-R Julian Chun
BACKGROUND Ablation strategies for patients with symptomatic atrial fibrillation and isolated pulmonary veins vary and their effects on arrhythmia recurrence remain unclear. A prospective randomized German multicenter trial sought to compare 2 ablation strategies in this patient cohort. METHODS Patients with atrial fibrillation despite durable pulmonary vein isolation were randomly assigned at 7 centers
-
Essential Role of the RIα Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development. Circulation (IF 35.5) Pub Date : 2024-10-02 Ibrahim Bedioune,Marine Gandon-Renard,Matthieu Dessillons,Aurélien Barthou,Audrey Varin,Delphine Mika,Saïd Bichali,Joffrey Cellier,Patrick Lechène,Sarah Karam,Maya Dia,Susana Gomez,Walma Pereira de Vasconcelos,Françoise Mercier-Nomé,Philippe Mateo,Audrey Dubourg,Constantine A Stratakis,Jean-Jacques Mercadier,Jean-Pierre Benitah,Vincent Algalarrondo,Jérôme Leroy,Rodolphe Fischmeister,Ana-Maria Gomez
BACKGROUND The heart expresses 2 main subtypes of cAMP-dependent protein kinase (PKA; type I and II) that differ in their regulatory subunits, RIα and RIIα. Embryonic lethality of RIα knockout mice limits the current understanding of type I PKA function in the myocardium. The objective of this study was to test the role of RIα in adult heart contractility and pathological remodeling. METHODS We measured
-
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation (IF 35.5) Pub Date : 2024-10-02 Niccolò Maurizi,Panagiotis Antiochos,Anjali Owens,Neal Lakdwala,Sara Saberi,Mark W Russell,Carlo Fumagalli,Ioannis Skalidis,Kimberly Y Lin,Ashwin S Nathan,Alejandro De Feria Alsina,Nosheen Reza,John C Stendahl,Dominic Abrams,Christopher Semsarian,Brian Clagget,Rachel Lampert,Matthew Wheeler,Victoria N Parikh,Euan Ashley,Michelle Michels,Joseph Rossano,Thomas D Ryan,Jodie Ingles,James Ware,Carolyn Y
BACKGROUND Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been systematically examined. METHODS Data from 13 high clinical volume HCM centers from the international SHARE (Sarcomeric Human Cardiomyopathy Registry) were analyzed
-
Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults. Circulation (IF 35.5) Pub Date : 2024-10-01 Roshan A Ananda,StellaMay Gwini,Lawrence J Beilin,Markus P Schlaich,Michael Stowasser,Morag J Young,Brendan Adler,Peter J Fuller,Trevor A Mori,Jun Yang
BACKGROUND Primary aldosteronism, characterized by renin-independent aldosterone production, is associated with adverse cardiovascular remodeling and outcomes. Elevated cardiovascular risk is observed even in subclinical forms of primary aldosteronism according to studies conducted primarily in middle-aged and elderly populations. This study aimed to assess whether early changes in primary aldosteronism
-
Unveiling the Hidden Layers of Hypertensive Heart Disease Through Quantitative PET Imaging. Circulation (IF 35.5) Pub Date : 2024-09-30 Andreas A Giannopoulos,Alessia Gimelli
-
Prescribing a New Treatment in Heart Disease Communication. Circulation (IF 35.5) Pub Date : 2024-09-30 Wyatt G Paltzer,Dietram A Scheufele
-
Coronary Artery Bypass Grafting: Past and Future. Circulation (IF 35.5) Pub Date : 2024-09-30 Marc Ruel,Joanna Chikwe
-
Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis. Circulation (IF 35.5) Pub Date : 2024-09-30 Lathan Liou,Mathew S Maurer,Amy R Kontorovich
-
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up. Circulation (IF 35.5) Pub Date : 2024-09-30 Peter R Sinnaeve,Robert C Welsh,Alexandra Arias Mendoza,Arsen D Ristić,Oleg V Averkov,Yves Lambert,José F Kerr Saraiva,Pablo Sepulveda,Fernando Rosell-Ortiz,John K French,Ljilja B Musić,Katleen Vandenberghe,Kris Bogaerts,Thierry Danays,Kevin R Bainey,Paul W Armstrong,Frans Van de Werf,
-
Clinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: Results From the Multicenter SAFE MRI ECMO Study. Circulation (IF 35.5) Pub Date : 2024-09-29 Sung-Min Cho,Shivalika Khanduja,Christopher Wilcox,Kha Dinh,Jiah Kim,Jin Kook Kang,Ifeanyi David Chinedozi,Zachary Darby,Matthew Acton,Hannah Rando,Jessica Briscoe,Errol L Bush,Haris I Sair,John Pitts,Lori R Arlinghaus,Audrey-Carelle N Wandji,Elena Moreno,Glenda Torres,Bindu Akkanti,Jose Gavito-Higuera,Steven Keller,HuiMahn A Choi,Bo Soo Kim,Aaron Gusdon,Glenn J Whitman,
BACKGROUND Early detection of acute brain injury (ABI) at the bedside is critical in improving survival for patients with extracorporeal membrane oxygenation (ECMO) support. We aimed to examine the safety of ultra-low-field (ULF; 0.064-T) portable magnetic resonance imaging (pMRI) in patients undergoing ECMO and to investigate the ABI frequency and types with ULF-pMRI. METHODS This was a multicenter
-
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial. Circulation (IF 35.5) Pub Date : 2024-09-29 Kieran F Docherty,Alasdair D Henderson,Pardeep S Jhund,Brian L Claggett,Akshay S Desai,Katharina Mueller,Prabhakar Viswanathan,Andrea Scalise,Carolyn S P Lam,Michele Senni,Sanjiv J Shah,Adriaan A Voors,Faiez Zannad,Bertram Pitt,Muthiah Vaduganathan,Scott D Solomon,John Jv McMurray
BACKGROUND The effect of treatments for heart failure may vary among patients according to left ventricular ejection fraction (LVEF). In the FINEARTS-HF, the nonsteroidal MRA finerenone reduced the risk of cardiovascular death and total worsening heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). We examined the effect of finerenone
-
Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation (IF 35.5) Pub Date : 2024-09-28 Muthiah Vaduganathan,Brian L Claggett,Ian J Kulac,Zi Michael Miao,Akshay S Desai,Pardeep S Jhund,Alasdair D Henderson,Meike Brinker,James Lay-Flurrie,Prabhakar Viswanathan,Markus Florian Scheerer,Andrea Lage,Carolyn S P Lam,Michele Senni,Sanjiv J Shah,Adriaan A Voors,Faiez Zannad,Bertram Pitt,John J V McMurray,Scott D Solomon
BACKGROUND Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. The sodium glucose-co-transporter-2 inhibitors (SGLT2i) and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined
-
Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study. Circulation (IF 35.5) Pub Date : 2024-09-26 Paul Friedman,Francis Murgatroyd,Lucas V A Boersma,Jaimie Manlucu,Bradley P Knight,Nicolas Clémenty,Christophe Leclercq,Anish Amin,Béla Merkely,Ulrika Birgersdotter-Green,Joseph Yat Sun Chan,Mauro Biffi,Reinoud Elwin Knops,Gregory Engel,Ignacio Muñoz Carvajal,Laurence M Epstein,Venkata Sagi,Jens Brock Johansen,Maciej Sterliński,Clemens Steinwender,Troy Hounshell,Richard Abben,Amy E Thompson,Yan Zhang
BACKGROUND Substernal lead placement of the extravascular implantable cardioverter-defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous ICDs and effective antitachycardia pacing (ATP), while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term
-
Associations of "Weekend Warrior" Physical Activity With Incident Disease and Cardiometabolic Health. Circulation (IF 35.5) Pub Date : 2024-09-26 Shinwan Kany,Mostafa A Al-Alusi,Joel T Rämö,James P Pirruccello,Timothy W Churchill,Steven A Lubitz,Mahnaz Maddah,J Sawalla Guseh,Patrick T Ellinor,Shaan Khurshid
BACKGROUND Achievement of guideline-recommended levels of physical activity (≥150 minutes of moderate-to-vigorous physical activity per week) is associated with lower risk of adverse cardiovascular events and represents an important public health priority. Although physical activity commonly follows a "weekend warrior" pattern, in which most moderate-to-vigorous physical activity is concentrated in
-
Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Circulation (IF 35.5) Pub Date : 2024-09-25 Robert Shaddy,Michael Burch,Paul F Kantor,Susan Solar-Yohay,Tania Garito,Sijia Zhang,Michele Kocun,Chad Mao,Antoinette Cilliers,Xu Wang,Charles Canter,Joseph Rossano,Gonzalo Wallis,Jondavid Menteer,Linda Daou,Jacek Kusa,Kursat Tokel,Daniel Dilber,Zhuoming Xu,Tingting Xiao,Nancy Halnon,Kevin P Daly,Matthew J Bock,Warren Zuckerman,Tajinder P Singh,Manisha Chakrabarti,Aviva Levitas,Michele Senni,Giorgia
BACKGROUND Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting
-
Effect of Delayed Remote Ischemic Preconditioning on Acute Kidney Injury and Outcomes in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial. Circulation (IF 35.5) Pub Date : 2024-09-25 Ping Jia,Qiang Ji,Zhouping Zou,Qi Zeng,Ting Ren,Weize Chen,Zhixin Yan,Daoqi Shen,Yang Li,Fangyuan Peng,Ying Su,Jiarui Xu,Bo Shen,Zhe Luo,Chunsheng Wang,Xiaoqiang Ding
BACKGROUND Remote ischemic preconditioning (RIPC) has 2 time windows for organ protection: acute and delayed. Previous studies have mainly focused on the organoprotective effects of acute RIPC. We aimed to determine whether delayed RIPC can reduce the occurrence of acute kidney injury (AKI) and postoperative complications in patients undergoing cardiac surgery. METHODS This prospective, single-center